Bristol Myers Squibb tops Q4 estimates
AstraZeneca bounds higher on Q4 beat, upbeat guidance
Novo Nordisk says it's not immune to potential Trump tariffs, but business is well-positioned
Pfizer taps a former Novartis exec to lead cancer drug push
*please scroll down for all the latest news*
